Skip to Main Content
Home
Search
Study Topics
Glossary
Full Text View
Tabular View
No Study Results Posted
Related Studies
Emergency Use Program for HTE HIV+ Patients Who Need Tipranavir Treatment
Expanded access is currently available for this treatment.
Study NCT00062660 Information provided by Boehringer Ingelheim Pharmaceuticals
First Received: June 10, 2003 Last Updated: November 23, 2009
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
HIV Infections
Additional conditions recognized in this trial
Acquired Immunodeficiency Syndrome
Emergencies
Infection
More general conditions related to this trial
Disease Attributes
Immune System Diseases
Immunologic Deficiency Syndromes
Lentivirus Infections
Pathologic Processes
Retroviridae Infections
RNA Virus Infections
Sexually Transmitted Diseases
Sexually Transmitted Diseases, Viral
Slow Virus Diseases
Virus Diseases
Interventions listed in this trial
Tipranavir Capsules
Tipranavir Oral Solution
Additional drug interventions recognized in this trial
Tipranavir
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antiviral Agents
Pharmacologic Actions
Therapeutic Uses
Sponsors listed in this trial
Boehringer Ingelheim Pharmaceuticals
Back to top of Main Content
